Colorectal Cancer
Conditions
Interventions
Setting: Hasan Sadikin Hospital.
Method of randomization: Simple randomization.
Method of concealment: sealed opaque envelopes.
Intervention: vitamin D 10,000 IU/day for six months.
Placebo: water
Sponsors
Andy
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male and female patients diagnosed with colorectal cancer based on the WHO histopathological classification system. 2. All stage II-III colorectal cancer patients undergoing adjuvant chemotherapy at Hasan Sadikin Hospital from May 2024 to April 2025. 3. Patients above 18 years of age.
Exclusion criteria
Exclusion criteria: 1. The patient has consumed vitamin D supplements in the last three months. 2. Allergy to vitamin D supplements. 3. The patient has a primary cancer other than colorectal cancer. 4. Patients with short bowel syndrome or patients undergoing gastric bypass surgery. 5. The patient regularly consumes phenobarbital, carbamazepine, dexamethasone, nifedipine, spironolactone, clotrimazole and rifampicin groups. 6. Patient with symptoms of genitourinary stones in the past year. 7. Patient is consuming a thiazide diuretic. 8. Patient with chronic non-infectious disease (liver failure and kidney failure, history of stroke, type I and II diabetes mellitus). 9. Patients with chronic infectious disease (infection lasts >6 months), such as HIV infection, tuberculosis, hepatitis C, HPV, et cetera. 10. Patients who are pregnant, breastfeeding or using oral contraceptives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of Vitamin D and EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30) score which contains 5 domains (Role, Physical, Cognitive, Emotional, and Social) [3- and 6-months post intervention] | — |
Countries
Indonesia
Contacts
Public ContactTovan Perinandika
General Surgeon
Outcome results
None listed